NMS·Healthcare·$2.3B·#160 / 520 in Healthcare
SRPT Sarepta Therapeutics, Inc.
57SPECULATIVE
CATEGORY BREAKDOWN
GROWTH25
QUALITY56
STABILITY73
VALUATION100
GOVERNANCE40
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+15.6%
25
> 50% strong
Gross Margin
Revenue retained after direct costs
61.8%
88
> 50% strong
Cash Runway
Months of cash at current burn rate
47 months
100
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
91.2%
18
< 25% strong
Price / Sales
Market cap relative to trailing revenue
1.1x
100
< 3x strong
Rule of 40
Growth rate plus operating margin
-14
9
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
4.1%
33
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+7.4%
55
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE SRPT WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when SRPT's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.